Diabetes breakthrough?
September 27, 2012
CSL Limited has developed an
entirely new approach to the
treatment of type 2 diabetes, which
it says may be able to prevent the
development of type 2 diabetes
and reverse its progression.
The research, published in Nature,
was a joint effort by an
international team led by Professor
Ulf Eriksson from the Karolinska
Institute in Sweden, and involving
scientists from CSL’s research
laboratories in Melbourne, The
University of Melbourne and the
Ludwig Institute for Cancer Research.
The research revolved around a
CSL drug candidate which blocks
signalling by a protein known as
Vascular Endothelial Growth Factor B
and this prevents fat from
accumulating in the “wrong” places,
such as in muscles and in the heart.
As a result, cells within these
tissues are once again able to
respond to insulin and blood
glucose is restored to normal levels.
“The results generated through
this international collaboration
represent a major breakthrough
and provide for a new way of
thinking about the treatment of
type 2 diabetes,” said obesity and
diabetes expert and co-author of
the paper, Professor Joe Proietto.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Sep 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Sep 12
